MAXY-G34: Final Phase IIa data

Final data from an open-label, Eastern European Phase IIa trial in 35 breast cancer patients showed that the 3 middle doses of MAXY-G34 (30, 45 and 60 ug/kg) had mean durations of severe neutropenia o...